Long-term immunogenicity of alternative HPV vaccine schedules and the effect of an additional dose given three to five years post-primary vaccination
InfectologiaResumo original em inglês
O que aconteceu
We assessed antibody persistence and the impact of an additional dose administered 42-60 months after initial vaccination. Girls initially vaccinated at ages 9-10 with two doses of quadrivalent HPV vaccine participated in two randomized trials: The 0-6-42HPV study which compared a quadrivalent and bivalent additional dose given at 42 months; The 0-6-60ICI-VPH study compared no additional dose to a quadrivalent dose at 60 months. HPV16/18 antibody detection and geometric mean concentrations (GMCs) were assessed (M9ELISA). Overall, 526 girls provided a blood sample. All had detectable HPV16/18 antibodies 10 years post-initial vaccination. An additional dose at 42 versus 60 months led to similar GMCs, both with higher immune responses compared to 2-dose group participants. Compared to the quadrivalent, the bivalent induced significantly higher HPV18 GMCs, which has unknown clinical significance. Two-dose schedule and delayed quadrivalent or bivalent additional doses are highly immunogenic, supporting long-term immunogenicity of alternative and mixed vaccination schedules.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Long-term immunogenicity of alternative HPV vaccine schedules and the effect of an additional dose given three to five years post-primary vaccination
Chantal Sauvageau, Iulia G Ionescu, Manale Ouakki, Gitika Panicker, Vladimir Gilca, Elizabeth R Unger, Marie-Hélène Mayrand
Descritores MeSH
- Papillomavirus Vaccines
- Immunogenicity, Vaccine
- Immunization Schedule
- Papillomavirus Infections
- Female
- Humans
- Human papillomavirus 16
- Vaccination
- Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
- Human papillomavirus 18
Veja também
Estudos relacionados
- Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls
- Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial
- Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine
- Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination